- Home
- LEGH vs VIR Comparison
LEGH vs VIR Comparison
Compare LEGH & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- VIR
- Stock Information
- Founded
- LEGH 2005
- VIR 2016
- Country
- LEGH United States
- VIR United States
- Employees
- LEGH N/A
- VIR N/A
- Industry
- LEGH Homebuilding
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- VIR Health Care
- Exchange
- LEGH Nasdaq
- VIR Nasdaq
- Market Cap
- LEGH 646.4M
- VIR 706.4M
- IPO Year
- LEGH 2018
- VIR 2019
- Fundamental
- Price
- LEGH $21.61
- VIR $5.88
- Analyst Decision
- LEGH Strong Buy
- VIR Strong Buy
- Analyst Count
- LEGH 1
- VIR 11
- Target Price
- LEGH $29.00
- VIR $25.73
- AVG Volume (30 Days)
- LEGH 97.2K
- VIR 1.3M
- Earning Date
- LEGH 11-11-2025
- VIR 10-30-2025
- Dividend Yield
- LEGH N/A
- VIR N/A
- EPS Growth
- LEGH 2.38
- VIR N/A
- EPS
- LEGH 2.23
- VIR N/A
- Revenue
- LEGH $184,284,000.00
- VIR $19,000,000.00
- Revenue This Year
- LEGH $1.51
- VIR N/A
- Revenue Next Year
- LEGH $7.92
- VIR $15.25
- P/E Ratio
- LEGH $9.72
- VIR N/A
- Revenue Growth
- LEGH 8.79
- VIR N/A
- 52 Week Low
- LEGH $20.85
- VIR $4.16
- 52 Week High
- LEGH $29.45
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- LEGH 19.15
- VIR 60.90
- Support Level
- LEGH $20.85
- VIR $5.52
- Resistance Level
- LEGH $27.59
- VIR $6.38
- Average True Range (ATR)
- LEGH 0.94
- VIR 0.32
- MACD
- LEGH -0.67
- VIR 0.03
- Stochastic Oscillator
- LEGH 11.00
- VIR 59.27
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.